VCNXOTCPharmaceutical PreparationsFiscal year ends December 31

VACCINEX, INC.

Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025

$1.00−0.01 (-0.99%)

Close on Oct 19, 2026

Market cap: $3.22M
P/E (TTM): –
Dividend yield: –

Dividends

Vaccinex has not reported a dividend

No dividend per share appears in Vaccinex's annual filings since fiscal 2016.

Where these numbers come from

Parsed from the XBRL in Vaccinex's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-14 reverse split on Apr 2, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VCNX.

Revenue growth5.4% · median -15.1%

Operating margin-3117.3% · median -6620.5%

Net margin-3100.5% · median -523.2%

Company	Revenue	Growth
RLYB	$646.00K	-15.1%
VCNX	$601.00K	+5.4%
YARW	$476.00K	-2.1%
GOVX	$0	-100.0%
ERNA	–	–
ANIX	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 23
Held by institutions: 0.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1205922

Advertisement
300 × 250